Literature DB >> 14872100

Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies.

J M Gómez-Zumaquero1, F J Tinahones, E De Ramón, M Camps, L Garrido, F J Soriguer.   

Abstract

OBJECTIVES: To study the levels of anti-oxidized low-density lipoprotein (LDL) antibodies in patients with systemic lupus erythematosus (SLE) at two different points during the disease, and evaluate their relation with markers of SLE activity in serial blood samples. To investigate the correlations at two points in time between anti-oxidized LDL antibodies and anti-beta2-glycoprotein-I antibodies, leucocytes, immunoglobulin G, anti-deoxyribonucleic acid, complement 3, complement 4 and the disease activity index.
METHODS: A total of 49 patients with SLE according to ACR criteria were studied at two points, 3 to 4 months apart, Time 1 and Time 2.
RESULTS: There were ostensible changes in levels of anti-oxidized LDL antibodies between Times 1 and 2, which correlated significantly with disease activity markers. The association between levels of anti-oxidized LDL antibodies and complement system activation remained after multiple regression analysis with stepwise adjustment.
CONCLUSIONS: Antibody levels against oxidized LDL vary with time and are closely related to the degree of SLE activity. There is an association between levels of autoantibodies to oxidized LDL and complement system activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14872100     DOI: 10.1093/rheumatology/keh109

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

Review 1.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 2.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 3.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

Review 4.  Cardiovascular disease in systemic lupus erythematosus.

Authors:  Maureen McMahon; Richard Seto; Brian J Skaggs
Journal:  Rheumatol Immunol Res       Date:  2021-12-15

5.  Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case-control study.

Authors:  E F H van Bommel; L J H van Tits; E A van den Berg; J Prins; A F H Stalenhoef
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

Review 6.  Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association.

Authors:  Maureen McMahon; Bevra H Hahn
Journal:  Curr Opin Immunol       Date:  2007-12       Impact factor: 7.486

Review 7.  Renal microvascular lesions in lupus nephritis.

Authors:  Ying Ding; Ying Tan; Zhen Qu; Feng Yu
Journal:  Ren Fail       Date:  2019-12-20       Impact factor: 2.606

8.  Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus.

Authors:  Lina Wirestam; Muna Saleh; Christina Svensson; Michele Compagno; Helene Zachrisson; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

Review 9.  Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Bevra H Hahn; Jennifer Grossman; Benjamin J Ansell; Brian J Skaggs; Maureen McMahon
Journal:  Arthritis Res Ther       Date:  2008-08-29       Impact factor: 5.156

Review 10.  Endothelial dysfunction in chronic inflammatory diseases.

Authors:  Curtis M Steyers; Francis J Miller
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.